摘要
目的:探讨低分子肝素钠联合贝那普利治疗2型糖尿病肾病的临床疗效。方法:对我科收治的64例糖尿病肾病患者,在常规降糖、降脂治疗下,随机分为低分子肝素联合贝那普利治疗组(T组,n=32)及单用贝那普利对照组(C组,n=32)。治疗8周后,分别比较两组治疗前、后平均动脉压(MAP)、24h尿蛋白、血清白蛋白(ALB)、尿白蛋白排泄(UAER)、血肌酐(Scr)的变化。结果:治疗后两组UAER均较治疗前有显著下降(P<0.05),T组较C组降低更显著(P<0.05);两组ALB较治疗前升高,且T组升高较C组明显(P<0.05);两组MAP有所下降(P<0.05),但两组间比较无显著性差异(P>0.05);两组Scr治疗前、后及组间比较,差异无统计学意义(P>0.05)。治疗组未见明显不良副作用。结论:低分子肝素与血管紧张转化酶抑制剂联合应用可降低糖尿病肾病患者的尿蛋白,提升血清白蛋白,延缓糖尿病肾病进程。
Objective： To compare and analyze the treatment effect of low-molecular-weight heparin and angiotensin converting anzyme（ACE） inhibitor（benazepril） on the type 2 diabetic nephropath. Methods： 64 patients with diabetic nephropathy were treated with conventional hypoglycemic, lipid-lowering treatment in our department. 64 patients were randomly divided into low molecular weight heparin combined with benazepril treatment group （T group, n=32） and benazepril alone control group （C group, n=32）. Compared mean arterial pressure （MAP）, 24 hours urinary protein, serum albumin （ALB）, urinary albumin excretion （UAER）, serum creatinine （Scr） changes before and after treatment. Results： UAER were significantly decreased after treatment（P〈0. 05）, T group decreased more significantly than C group （P〈0.05） ; the ALB higher than that before treatment and T group were significantly higher than C （P〈 0. 05）;MAP decreased in two groups （P〈 0. 05）, but there was no significant difference between the two groups showed （P〉0. 05）;the Scr between two groups was not statistically significant （P〉0. 05）. No obvious adverse side effects in treatment group. Conclusion： Low-molecular-weight heparin combination with angiotensin converting enzyme inhibitors can reduce urinary protein in patients with diabetic nephropathy, improve serum albumin, delaying the process of diabetic nephropathy.
出处
《医学理论与实践》
2012年第10期1150-1151,共2页
The Journal of Medical Theory and Practice
关键词
低分子肝素
贝那普利
糖尿病肾病
Low-molecular-weight heparin, Benazepril, Diabetic nephropath
